61 results about "Tumor immunosuppression" patented technology

The invention discloses a cell membrane protein replacement type oncolytic virus vector and application thereof. The cell membrane protein replacement type oncolytic virus vector is rhabdoviridae virus, and a nucleotide sequence for coding G protein in a genome of the rhabdoviridae virus is replaced by a nucleotide sequence for coding an antibody and a nucleotide sequence for coding a spike protein truncation of coronavirus. The invention also discloses a construction method of the cell membrane protein replacement type oncolytic virus vector for expressing the antibody, the non-replicated virus vector is used for expressing the antibody sequence for the first time, and meanwhile, the novel coronavirus cell membrane protein is embedded into the virus surface, so that the cell membrane protein replacement type oncolytic virus vector can be rapidly produced in a suspension cell in a large scale; through removal of virus cell membrane protein genes, the virus cell membrane protein genes cannot be continuously replicated in vivo, so that the safety of the virus cell membrane protein genes is ensured, the tumor immunosuppression condition is improved, and an organism can be stimulated to generate a neutralizing antibody for resisting new coronavirus while tumor cells are killed.

The invention relates to the technical field of biological medicines, in particular to a CKAP4-targeted tumor antigen peptide, a vaccine and application of the CKAP4-targeted tumor antigen peptide. The invention provides a high-immunogenicity tumor antigen peptide RLTELTKSI targeting human and mouse homologous CKAP4 protein, and the tumor antigen peptide and a vaccine thereof can realize efficient killing of CKAP4 positive tumor cells and remarkable inhibition of CT26 subcutaneous tumor by activating specific CD8 + T cell immune response. The traditional single-target limitation is broken through, the co-expression characteristic of CKAP4 in tumor cells and immunosuppressive cells (TAM / TAN) is utilized, a double-target and double-channel mechanism is initiated, and the immunosuppressive state of cold tumors is effectively reversed by inducing T cells to synchronously kill tumor cells and remodel an immune microenvironment. According to the technology, CKAP4 is expanded from an antibody target to a T cell vaccine target, lasting specific CTL response can be stimulated, the off-target risk of antibody treatment is avoided, a universal treatment scheme can be provided for solid tumors, and the clinical transformation potential and the treatment broad spectrum are remarkably improved.

The invention belongs to the technical field of microorganisms, and particularly relates to combined lactobacillus salivarius and application thereof in female genital tract health. The preservation number of the strain is CCTCC NO: M20231719, and the strain has good bacteriostatic ability and dendritic cell (DC) maturation / activation stimulation ability, has no potential safety problem, can regulate vaginal micro-ecological balance, prevent infection caused by exogenous bacteria, effectively improve tumor immunosuppression microenvironment, and has good application prospects. And the method has very important significance on prevention / treatment of vaginal dysbacteriosis patients, gynecological tumors and precancerous lesions thereof.

The present invention relates to a complex comprising a polysaccharide conjugate, an anti-PD-L1 monoclonal antibody, and a PKM2 inhibitor. The complex of the present invention can accumulate and remain in tumor tissue, effectively stimulate dendritic cell maturation, alleviate the inhibitory immune microenvironment, and trigger a specific anti-tumor immune response. It can effectively inhibit the expression of PKM2, thereby inhibiting glycolysis in tumor tissue and providing a more favorable environment for T lymphocytes to infiltrate tumor tissue. The complex of the present invention is expected to enhance the therapeutic effect of RFA on patients with advanced HCC by reprogramming iRFA-induced tumor immunosuppression, and has great potential in improving the prognosis of patients with advanced HCC treated with RFA.

This invention discloses a composite nanozyme that enhances the clinical efficacy of oxaliplatin, its preparation method, and its application. The composite nanozyme consists of indium ruthenium nanozyme and an iliximab embedding and anchoring layer. The indium ruthenium nanozyme consists of indium ruthenium nanoparticles and a carbon-nitrogen framework, with the indium ruthenium nanoparticles loaded on the surface and within the pores of the carbon-nitrogen framework. The iliximab embedding and anchoring layer consists of a dithiol polyethylene glycol coating layer and iliximab. Preparation method: ZIF-8 is prepared by co-precipitation of zinc salt methanol solution and 2-methylimidazole methanol solution, followed by calcination to obtain the carbon-nitrogen framework. The carbon-nitrogen framework dispersion is then stirred in an oil bath with indium nitrate solution and ruthenium trichloride solution to prepare a nanozyme precursor, followed by calcination to obtain indium ruthenium nanozyme. The indium ruthenium nanozyme is dispersed in a dithiol polyethylene glycol solution, and iliximab solution is added dropwise. The resulting solid product is then dried. This invention can solve problems such as strong drug tolerance, insufficient intracellular accumulation, and severe tumor immunosuppression in oxaliplatin treatment.

Provided are methods for treatment of cancer using multispecific molecules that specifically bind to human CD96 and human TIGIT, and combinations of these molecules with human PD-1 inhibitors. These methods are particularly advantageous in that the combination of anti-human CD96 / TIGIT multispecific molecules and PD-1 inhibitors described herein potently increase immune cell responsiveness and activation, effectively enhancing anticancer immunity and overcoming tumor immunosuppression to treat cancer.

The invention relates to the technical field of biology, in particular to a preparation method and application of a bionic nano regulator. The invention provides a bionic nano regulator. The nano regulator comprises a therapeutic drug; the therapeutic drug is prepared from Ce6 and SB525334. And extruding the bacterial outer membrane vesicles and the PLGA encapsulating the Ce6 and SB525334 medicines to obtain the bionic nano regulator. Under photodynamic therapy, the bionic nano regulator can be recognized, taken and delivered to tumor tissues by neutrophils. The bionic nano regulator can regulate and control polarization of neutrophil to an anti-tumor N1 type, promote the neutrophil to release neutrophil elastase, specifically kill tumor cells and reverse a tumor immunosuppression microenvironment. Under the combined treatment of photodynamic-immunotherapy, the biomimetic nano regulator obviously inhibits tumor growth and enhances the anti-tumor immune response of the body.

The present application relates to the technical field of polymer chemistry, and particularly relates to a responsive dendritic polyamino acid modified polyurethane and a preparation method and application thereof.The responsive dendritic polyamino acid modified polyurethane has a structure shown in formula I.The responsive dendritic polyamino acid modified polyurethane provided by the present application can specifically expose positive dendritic polylysine in the unique acidic environment of tumor tissue, trigger immunogenic death of tumor cells, release tumor antigens, and comprehensively activate an anti-tumor immune response.Meanwhile, the positive dendritic polylysine causes an increase in reactive oxygen species (ROS) of tumor cells, oxidizes a diselenium bond in the polyurethane into selenic acid, reduces the expression of immune checkpoints of tumor cells, reverses the immunosuppressive microenvironment of tumor tissue, realizes synergistic treatment of immune activation and reversal of the tumor immunosuppressive microenvironment, and realizes a better tumor immunotherapy effect.

The invention discloses an application of indole-3-pyruvic acid in preparation of an NF-kappa B signal channel activator. The research on the influence of the indole-3-pyruvic acid on NF-kappa B signal channels in breast cancer cells and killer T cells (CD8 + T cells, Tc) proves that the indole-3-pyruvic acid can activate the NF-kappa B signal channels in the breast cancer cells and the CD8 + T cells, so that the indole-3-pyruvic acid can be used for preparing the medicine for improving the tumor immunosuppressive microenvironment.

The invention relates to the field of biological medicine, and discloses application of PCA and PD-1 antibodies in drug combination for treating liver cancer. It is found that the flora metabolite PCA can improve the tumor immunosuppression microenvironment and enhance the effect of the PD-1 monoclonal antibody in liver cancer treatment, so that the responsiveness of liver cancer to PD-1 monoclonal antibody immunotherapy is improved, the lifetime is prolonged, and prognosis is improved.

The invention discloses preparation and application of a PD-L1 nano-inhibitor capable of enhancing the immunotherapy effect of cervical cancer, and belongs to the field of nano-drugs. According to the invention, PDA-coated double-high-Z metal nanoparticles, GdPt-coated PDA for short, are synthesized by using a solvothermal method and a solution oxidation method. Compared with the prior art, the GdPt-coated PDA has an excellent immunotherapy effect and good biological safety. The GdPt (at) PDA not only can realize immunotherapy by down-regulating the expression level of PD-L1, but also can improve the tumor immunosuppression microenvironment and promote immune cell infiltration in tumors through combined radiotherapy, and cooperates with alphaCTLA-4 to realize dual-immune checkpoint blocking therapy, thereby successfully inhibiting the growth of primary tumors and distant tumors.

Disclosed are preparation and anti-tumor application of a gene therapy vector interfering CKLF-like MARVEL transmembrane domain-containing protein 6 (CMTM6) expression. Specifically, disclosed are a gene therapy vector encoding a gene sequence targeting CMTM6 and a derivative thereof, a gene sequence encoded by a vector, a preparation method, and a use of a vector alone and in combination with other drugs in treating tumors. These gene therapy vectors comprise adeno-associated viruses and lentiviruses, etc., can inhibit the expression of CMTM6 in tumor tissues, can effectively inhibit the in-vivo growth of mouse and human colorectal cancer, melanoma, liver cancer, breast cancer, non-small cell lung cancer and the like by improving the tumor immunosuppression microenvironment, exhibit a strong anti-tumor effect in combination with immune checkpoint antibodies, chemotherapeutic drugs, immunoagonistic drugs, and metabolic regulation drugs, and have significant efficacy on PD-L1-deficient tumors and immune checkpoint antibody drug-resistant tumors.

The invention discloses an application of a tumor targeting NNMT inhibitor in preparation of a drug-resistant tumor resistant drug. The NNMT inhibitor comprises an NNMT inhibitor dipeptide and a physiologically acceptable salt of the NNMT inhibitor dipeptide. The NNMT inhibitor can target tumor microenvironment FAP < + > / NNMT < + > extravascular stromal cells, reduce the expression of drug resistance promoting factors, induce blood vessel normalization, improve the infiltration of killer T cells, block the formation of tumor immunosuppression microenvironment, and enhance the curative effects of tumor immunotherapy and anti-angiogenesis therapy. The NNMT inhibitor has a remarkable immunotherapy or anti-angiogenesis treatment sensitization effect on colorectal cancer, pancreatic cancer, breast cancer, lung cancer, liver cancer, stomach cancer, prostatic cancer, ovarian cancer, melanoma and the like, and has a good application prospect in the aspect of preparing anti-drug-resistant tumor drugs.

The application discloses a kind of lipid nano-drug delivery system and its preparation method in the application of improving tumor vascular normalization, the lipid nano-drug delivery system includes drug, CaO2 Nanoparticle and anionic liposome, the drug and CaO2 Nanoparticle are co-loaded in the anionic liposome;The surface of the CaO2 Nanoparticle is with positive charge, and the preparation raw material of the anionic liposome contains 1,2-dioleoyl-sn-glycerol-3-phosphoric acid sodium salt. 2+ The lipid nano-drug delivery system can enhance endothelial cell-derived NO production by mediating eNOS activation of Met and other drugs and Ca

The invention discloses a bionic photo-thermal nano motor for targeted regulation and control of a solid tumor matrix-immunosuppression microenvironment and a preparation method and application thereof, and belongs to the technical field of biomedical materials.The preparation method comprises the steps that polydopamine nanoparticles and a K2PtCl4 aqueous solution are subjected to condensation reflux, and asymmetric PDA-Pt is prepared; and preparing a cancer-related fibroblast and breast cancer cell fusion membrane and coating the surface of PDA-Pt with the cancer-related fibroblast and breast cancer cell fusion membrane. The nano-motor realizes dual targeting of matrix cells and tumor cells through a surface modified fusion cell membrane, targeted ablation CAFs regulates and controls a tumor matrix microenvironment, a good tumor permeation effect is realized by cooperating with H2O2 responsive self-driving of the nano-motor, a mild photo-thermal-catalytic synergistic effect is formed by a photo-thermal effect of PDA and peroxidase-like activity of Pt nano-enzyme, and a good tumor permeation effect is achieved. And finally, the tumor immunosuppression microenvironment is remarkably improved, and the tumor immunotherapy effect is improved.

The invention relates to a thermo-sensitive hydrogel drug sustained-release stent for jointly loading a hypotensive drug and a chemical / immunotherapy drug, which is prepared from a thermo-sensitive material and loads three drug components, namely losartan, oxaliplatin and an immune checkpoint inhibitor. The temperature-sensitive hydrogel can form gel in situ under the triggering of body temperature, and meanwhile, the acting time of the medicine on a target part is prolonged. The antihypertensive drug losartan potassium can reduce tumor interstitial substances, reduce tumor solid stress, relieve vascular compression in tumors and improve tumor hypoxia. Meanwhile, the chemotherapeutic drug oxaliplatin can induce tumor immunogenic cell death, and the tumor immunosuppressive microenvironment is effectively relieved. The immune checkpoint inhibitor can be used for accurately blocking the combination of the PD-L1 and the PD-1 and activating the T cell mediated anti-tumor immune response. According to the present invention, the potent anti-tumor immune response can be triggered, the excellent tumor inhibition effect can be achieved, the strong far-end effect can be even induced, and the growth of the far-end tumor can be effectively inhibited.

This invention relates to a liposomal formulation based on myeloid cell regulation and chemotherapy enhancement, along with its preparation method and antitumor applications, belonging to the technical field of pharmaceutical formulations. The liposomal formulation uses liposomes as carriers to co-load the CD11b agonist leukadherin-1 (LA1) prodrug (DSPE-PEG2000-Azo-LA1) and the gemcitabine prodrug Gem-SS-Chol. DSPE-PEG2000-Azo-LA1 contains a hypoxia-responsive azobenzene linker, and Gem-SS-Chol contains a glutathione-responsive disulfide bond, enabling precise drug release within the tumor microenvironment. This formulation exhibits uniform particle size and good stability, synergistically exerting chemotherapeutic and immunomodulatory effects. It effectively inhibits the proliferation and migration of pancreatic cancer tumor cells, enhances tumor cell immunogenic cell death, regulates the phenotype of myeloid immune cells in the tumor immunosuppressive microenvironment, and improves the therapeutic effect of pancreatic cancer. This invention provides a novel and highly efficient liposomal formulation for pancreatic cancer treatment, focusing on myeloid cell regulation and chemotherapy enhancement.

This paper proposes a tumor-associated fibroblast-targeted nanosystem, consisting of PLGA nanoparticles co-encapsulating anti-fibrotic and anti-aging drugs as the core, and a 4T1 cell membrane expressing a specific FAP chimeric antigen receptor as the biomimetic shell. The present invention constructs FAP-CAR-4T1 cells by embedding FAP scFv onto 4T1 cells. FAP-CAR-CM@PLGA NPs co-encapsulate anti-fibrotic and anti-aging drugs, enabling FAP-CAR-CM@PLGA-AB NPs to target CAFs and SC CAFs, improving radiotherapy resistance and achieving a dual clearance effect while simultaneously relieving the tumor's immunosuppressive microenvironment, effectively reducing breast cancer recurrence after radiotherapy.

This invention discloses a nanocomposite loaded with PD-L1 siRNA and an anti-tumor peptide, its preparation, and its application in treating renal cell carcinoma. The nanocomposite uses a dendritic macromolecule as its carrier, and the loaded peptide is Tat-HSPB1, whose amino acid sequence is shown in SEQ ID NO.1. The amino acid sequence of the loaded PD-L1 siRNA is shown in SEQ ID NO.2. The composite of this invention utilizes multiple interactions between phenylboronic acid, nucleic acids, and peptides to achieve stable co-assembly and acid-responsive intracellular release. While reducing the cytotoxicity of high-generation dendritic macromolecules, it effectively delivers siPD-L1 to specifically downregulate PD-L1 expression in renal tumor cells, thereby relieving tumor immunosuppression. Synergistically, with the anti-tumor activity of Tat-HSPB1 itself, this composite can significantly induce tumor cell death and inhibit its proliferation, providing a novel, highly efficient, and low-toxicity strategy for renal cell carcinoma immunotherapy.

The invention discloses an application of sodium cromoglycate in preparation of a pharmaceutical composition for promoting immunotherapy of breast cancer, and belongs to the technical field of tumor therapy, and the breast cancer is breast cancer with immunotherapy failure or immunotherapy drug-resistant breast cancer. The invention provides an application of sensitizing an immunotherapy drug in treatment of breast cancer by inducing antigen presenting related functional molecules on antigen presenting mast cells to be up-regulated by using sodium cromoglycate, remarkably enhancing antigen presenting mast cell mediated T cell anti-tumor immunity and inhibiting tumor growth resistant to immunotherapy. The sensitization immunotherapy curative effect of a mouse experiment shows that the sodium cromoglycate combined immunotherapy inhibits the growth of mouse breast tumor resistant to immunotherapy, and the prospective II-stage clinical test proves that the immunotherapy combined sodium cromoglycate has the curative effect and safety on a patient suffering from the triple negative breast cancer resistant to immunotherapy, and the immunotherapy combined sodium cromoglycate can be used for treating the triple negative breast cancer resistant to immunotherapy. The preset main curative effect end point is reached, and the adverse reaction is controllable.

The disclosure provides, in various aspects, methods of treating cancer in a subject in need of treatment therefor, comprising administering to the subject a therapeutically effective amount of an osteoprotegerin inhibitor, wherein the osteoprotegerin inhibitor inhibits osteoprotegerin binding to TRAIL. In further aspects, the disclosure provides methods of achieving a therapeutic outcome in a subject in need of treatment, wherein the method comprises the administration to the subject of a treatment which inhibits OPG-mediated suppression of tumor immunity.

According to the invention, a nano molecular system (ACu-NPs) based on amifostine and copper ions is innovatively constructed. According to the system, Cu < 2 + > is specifically released through a tumor microenvironment, the problem of non-specific distribution of copper ions in vivo is effectively solved, and toxicity to normal cells is avoided. Through a Fenton-like reaction catalyzed by Cu (II) / Cu (I), the system can consume glutathione (GSH) in tumor cells, promote generation of reactive oxygen species (ROS), remarkably reverse a tumor immunosuppression microenvironment and overcome the problem of low response rate of an immune checkpoint blocking (ICB) therapy. Besides, ACu-NPs generates WR-1065 through metabolism of alkaline phosphatase (ALP) in normal cells, ROS is removed, the normal cells are protected against oxidative damage, and the problem of toxicity of a traditional copper ion carrier to normal tissues is effectively solved. The invention provides an innovative dual treatment strategy for treating primary and metastatic tumors.

The invention relates to a nanofiber vaccine combined medicine and application thereof. The combined medicine comprises a first preparation and a second preparation, the first preparation is 6-thio-2 '-deoxyguanosine; the second preparation is a nanofiber vaccine, and the nanofiber vaccine comprises an E744-62-Q11 nanofiber vaccine or a Q11-M30 nanofiber vaccine; the invention relates to an E744-62-Q11 nanofiber vaccine, which is formed by connecting a synthesized self-folding peptide Q11 and an HPV16E7 antigen peptide through gene fusion and self-assembling in vitro, the invention relates to a Q11-M30 nanofiber vaccine, which is formed by self-assembling a synthesized self-folding peptide Q11 and a mouse melanoma B16-F10 tumor antigen M30 in vitro. The invention finds that THIO has a direct regulation effect on a key immunosuppressive cell MDSC, and reveals that THIO can directly down-regulate tumor immunosuppression and remodel a tumor microenvironment; the THIO and the nanofiber vaccine are combined for use, the tumor cell specific killing and TME regulation potential of the THIO is disclosed, the THIO and a tumor vaccine stimulate effector cell response to generate a synergistic anti-tumor effect, and a new strategy is provided for combined immunotherapy for inducing tumor ICD based on the THIO.

The invention provides an anti-MIC humanized single-chain antibody as well as a coding gene, an expression vector, a host, a conjugate or conjugate, an adsorbent and application thereof, and the humanized single-chain antibody provided by the invention can be specifically combined with an NKG2D ligand in human blood or plasma so as to relieve a tumor immunosuppression effect caused by abnormal increase of soluble MIC protein. Compared with the traditional antibody, the humanized single-chain antibody provided by the invention has the advantages of small molecular weight, strong stability, low immunogenicity, low cost, easy expression and high expression quantity, and is suitable for large-scale production. According to the invention, the humanized single-chain antibody is combined with the solid-phase carrier, so that the adsorption efficiency is high, the adsorption performance is stable, the non-specific adsorption capacity on other proteins in plasma is low, the specificity is good, the safety performance in clinical treatment is good, and the economic benefit is high. In addition, the humanized single-chain antibody provided by the invention reduces side effects caused by falling of adsorption ligands, and improves safety.

The invention relates to the technical field of polymer chemistry, in particular to responsive dendritic polyamino acid modified polyurethane as well as a preparation method and application thereof. The responsive dendritic polyamino acid modified polyurethane has a structure as shown in a formula I which is described in the specification. The responsive dendritic polyamino acid modified polyurethane provided by the invention can specifically expose electropositive dendritic polylysine in a unique acidic environment of tumor tissues, trigger immunogenic death of tumor cells, release tumor antigens and comprehensively activate anti-tumor immune response. Meanwhile, the positive electricity dendritic polylysine causes the rise of reactive oxygen species (ROS) of tumor cells, a diselenide bond in polyurethane is oxidized into selenic acid, the expression of immune checkpoints of the tumor cells is reduced, the immunosuppression microenvironment of tumor tissues is reversed, and collaborative treatment of immune activation and tumor immunosuppression microenvironment reversal is realized. And a better tumor immunotherapy effect is achieved.

The ICAM-1 / CD54 protein has been found to be a suppressor of antibody-mediated humoral immunity facilitated through its direct binding to the CH3 domain within IgG1 heavy chains. Its binding suppresses antibody immune-effector activity by reducing IgG1 engagement with Fc receptors on effector cells and C1q complement initiating protein. In addition, its binding has the potential to reduce antibody drug conjugate activity by slowing target cell internalization. Engineered antibodies with CH3 region modifications can be generated that reduce or eliminate ICAM-1 / CD54 binding leading to antibodies with improved immune-effector activity and antibody drug conjugate killing in the presence ICAM-1 / CD54. These antibodies can be useful to treat patients with cancer and inflammatory and infectious diseases exhibiting elevated ICAM-1 / CD54 levels.

The invention relates to the technical field of nano biological medicines, in particular to manganese-based biomineralized nanoparticles for preparing a medicine for treating HER2 positive breast cancer as well as a preparation method and application of the manganese-based biomineralized nanoparticles. The manganese-based biomineralized nanoparticles are formed by self-assembly of Mn < 2 + > under an alkaline condition by using tandem multifunctional DNA as a biological template; the tandem multifunctional DNA comprises a DNA enzyme sequence of a targeted silence HER2 gene and a double-stranded DNA functional unit used for activating a cGAS-STING signal channel. The nanoparticle has the characteristic of dual response release of pH and glutathione, has a better release effect under an acidic or glutathione-containing condition, and releases series multifunctional DNA and Mn < 2 + > in a targeted manner in a special microenvironment of tumor cells to silence HER2 and cooperatively activate a cGAS-STING pathway, cooperatively inhibit proliferation and migration of tumor cells and remodel a tumor immunosuppression microenvironment, so that the tumor immunosuppression effect is improved, and the tumor immunosuppression effect is improved. The natural immune response of tumors is enhanced.

The invention discloses a lipid platinum prodrug assisted RNA (Ribonucleic Acid) lipid nanoparticle as well as preparation and application thereof, and is characterized in that the lipid platinum prodrug assisted RNA lipid nanoparticle comprises SM-102, DSPC (Distearoyl Phthalate), cholesterol, DMG-PEG (Dimethyl Glycol-Polyethylene Glycol), a lipid platinum prodrug and RNA; the lipid platinum prodrug comprises a platinum drug and fatty acid, the RNA comprises siRNA and mRNA, the siRNA is used for targeted regulation of tumor immunosuppression related genes (such as PS exposure related genes), and the mRNA is used for coding antigen protein to activate immune response. According to the invention, not only is the protection on RNA improved, but also the adsorption of the LNPs on the RNA is increased, and a foundation is laid for an effective cis-platinum-RNA collaborative delivery system.

The invention discloses a nano-engineered mononuclear cell and application thereof, and belongs to the technical field of medicines. The nano-engineered mononuclear cell comprises a mononuclear cell, a nano-engineered element and a therapeutic drug, the nano-engineered element is loaded in cytoplasm of the mononuclear cell, and the surface of the mononuclear cell is modified with the therapeutic drug; the nano engineered element is iron oxide nanoparticles; the therapeutic drug is a functional lipid obtained by modifying a chemotherapeutic drug on a lipid molecule. The nano-engineered mononuclear cell can retain and even enhance the tumor tropism and tumor infiltration capacity of the mononuclear cell, can effectively intervene in the differentiation phenotype of the mononuclear cell in vivo and in vitro, relieves the tumor immunosuppression microenvironment, inhibits the growth of tumor cells, and achieves a good anti-tumor effect.

The present invention discloses an immune-assisted patch for preventing postoperative tumor recurrence and a preparation method thereof. The patch uses hydrophilic chitosan as a matrix, and the immune active components are dissolved, dispersed and mixed with the matrix, and then placed in a mold for solidification and molding; the immune active components are immune antibodies and immune adjuvants. The immune-assisted patch prepared by the present invention uses hydrophilic medical chitosan to electrostatically adsorb positively charged LDHs functional nanomaterials with acid regulation properties and anti-tumor immune adjuvant properties, and electrostatically adsorbs therapeutic antibodies that carry rich amino groups and can reverse tumor immunosuppression, and finally assembles into a biofunctional patch that can be disassembled under physiological conditions of the wound. The present invention has the characteristics of safe application and excellent performance, and is expected to serve as a new postoperative immune-assisted solution to promote tumor cure and benefit patients, and improve the long-term survival rate and quality of life of postoperative patients.